NetFlix Inc vs BIO-TECHNE Corp — how do they compare? NetFlix Inc trades at $68.33 (market cap $281.48B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: NetFlix Inc is far larger — about 25.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | TECH | |
|---|---|---|
Market Cap | $281.48B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $126.33 | $72.12 |
52-Week Low | $67.60 | $43.31 |
Enterprise Value | $286.66B | $11.24B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.
The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →